Company Overview and News
KUALA LUMPUR, Oct 11 — Bursa Malaysia ended in the red amid broad selling activities and in line with Asian markets as investors remained on the sidelines on heightened volatility in the global markets, said a dealer.
GMALF 7036 4197 5199 GMALY 5225 4715 SMEBF Q0F BSMAF IHHHF HIPEF 1818
KUALA LUMPUR (Oct 11): The FBM KLCI dropped 26.69 points or 1.54% today to end at 1,708.49 in tandem with Asian shares on what appeared to be a knee-jerk reaction to US stocks' overnight tumble.
GMALF UPBMF 2089 6033 CIMDF GMALY 1023 PNADF 5225 4715 Q0F IHHHF PNAGF
Selling pressure on the local market gained strength following a slew of announcements by the government, from greater competition in the telecommunications sector to the termination of MMC Gamuda KVMRT (T) Sdn Bhd’s contract for the mass rapid transit Line 2 (MRT2) and introduction of new taxes.
GMALY 1562 4863 5347 4715 GMALF 6888 TNABY AXXTF MYTEF TNABF GEBHF
KUALA LUMPUR (Oct 10): Axiata Group Bhd, Telekom Malaysia Bhd (TM) and Genting Bhd were the three biggest laggards among the FBM KLCI component stocks in the afternoon session.
GMALF 5168 6033 7277 CIMDF GMALY 1023 PNADF 4863 5347 4715 TNABY 6888 AXXTF MYTEF TNABF PNAGF GEBHF HRGHY
KUALA LUMPUR, Oct 2 ― Bursa Malaysia was higher at today's closing on continued buying in selected heavyweights, namely Genting Malaysia, Genting Bhd and Nestle, which together contributed 2.39 points to the gains in the composite index.
GMALY PBLOF 4715 0026 GMALF 5819 1295 BSMAF HIPEF GEBHF 1818 5199
KUALA LUMPUR: Continuous buying by funds and gains on heavyweights helped propel the benchmark FBM KLCI index higher on Tuesday. The FBM KLCI added 5.69 points, or 0.32%, to close at 1,798.15 on strong interest in Genting Group stocks as well banking stocks. The market traded within a range of 5.53 points between an intra-day high of 1,797.20 and a low of 1,791.67 during the session. Market breadth was negative with 554 gainers, 376 losers and 365 counters unchanged on the Bursa Malaysia.
GMALY HLFBF 4863 4715 GMALF 1082 MYTEF BSMAF 1818
KUALA LUMPUR (Sept 21): The FBM KLCI rose 0.39% at midday break Friday, tracking gains at regional markets, as worries over the US-China trade tensions abated somewhat.
7084 7052 GMALF 5681 BATS 4162 5134 7079 GMALY 5139 KLKBY 2445 3301 4715 7216 0900 0026 2836
KUALA LUMPUR (Sept 20): The FBM KLCI pared some of its gains and was up 0.28% at midday break, while remaining above the crucial 1,800-point level, in line with the advance at most regional markets.
HLFBF APEXF 7052 5183 7090 GMALF PECGF 1082 2291 0096 5256 9334 5134 7277 5199 GMALY 5436 4588 3026 4715 5819 2836 HIPEF
(Sept 20): Most Southeast Asian stock markets rose on Thursday, in line with Asian peers and overnight gains on Wall Street, while investors took heart as Sino-U.S. trade war pressures seemed to have eased.
GMALY SMPH ICT 4715 GMALF SPHXY SPHXF ICTEF SPHZF
KUALA LUMPUR (Sept 20): The FBM KLCI rose 0.46% at mid-morning, tracking gains at the regional markets, lifted by select index-linked blue chips.
HLFBF 7052 GMALF 1082 BATS 4162 0096 5256 5199 GMALY 5139 5258 3301 4715 0900 5208 5819 2836 HIPEF
Genting Malaysia Bhd (Sept 18, RM4.87) Maintain buy with an unchanged target price of RM5.70: Genting Malaysia Bhd has announced that the US federal government, via the Department of Interior (DoI), had recently issued a decision stating that the Mashpee Wampanoag Tribe would not be granted the disputed land in trust for developing the First Light Resort & Casino (FLRC) in Taunton, south of Boston, the US.
GMALY 4715 GMALF
Visitor count to the hilltop resort increased by 21% year-on-year to 12.8 million as of June, due to the new facilities opened under the Genting Integrated Transformation Plan that included the SkyCasino, SkyAvenue mall and Awana Skyway cable car.
GMALY 4715 GMALF
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...